Amgen to present its four Phase 3 clinical trial results

Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa(R) (zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer (the '136' study) and the treatment of bone metastases in advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma (the '244' study).

Detailed data will also be presented from two Phase 3 studies evaluating Vectibix(R) (panitumumab) in combination with chemotherapy for the first-line and second-line treatment of metastatic colorectal cancer (the '203' and '181' trials, respectively).

"Amgen is very pleased to be presenting these important data from the denosumab and Vectibix development programs," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "The data from these trials demonstrate that both denosumab and Vectibix have the potential to improve outcomes in patients suffering from cancer."

http://www.amgen.com/